USA-FDA approved safety trial done in USA proving safety of an allogeneic, human, umbilical cord blood-derived mesenchymal stem cells hUCB-MSCs that are used to treat patients.
Click here to learn more.
Concussions
Clinical trials investigating mesenchymal stem cells (MSCs) for the treatment of concussions and traumatic brain injury (TBI) have primarily focused on safety, functional recovery, and neuroprotection. While most studies target moderate to severe TBI, the underlying mechanisms and outcomes are relevant to concussion management, especially in cases with persistent symptoms or post-concussion syndrome.
Clinical trial linked here:
https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2025.1472679/full
Treatment for Early Signs of Dementia
The MSCs as results of safety trial reviewed by the medical professionals at the Orthopedic Journal of Sports Medicine Journal. No allergic reaction to the MSCs was indicted.
USA-FDA approved safety trial done in USA proving safety of an allogeneic, human, umbilical cord blood-derived mesenchymal stem cells hUCB-MSCs that are used to treat patients: Publication in Orthopedic Journal of Sports Medicine
MSCs are produced in a commercial Good Manufacturing Process I (GMP) is in Seoul Korea in a Korean FDA approved GMP which produces hUCB-MSCs from donated umbilical cord blood. The process of manufacturing the hUCB-MSCs from cord blood takes about 4 to 6 months. This Korean GMP has been manufacturing hUCB-MSCs since 2012 This GMP is audited by Korean FDA. there has not been one reported case of an adverse reaction to the MSCs in the treatment of thousands of patients. The Korean FDA approved GMP is located in Seoul Korea which provides the MSCs flown to Nassau Bahamas as required to treat patients at the Zemyna Clinic. The HUCB-MSCs can be used by any patient regardless of blood type, age, sex or ethnicity. The hUCB-MSCs to treat patients are 20 million MSCs per treatment.
Controlled clinical trial showing efficacy of MSCs for early dementia
Stroke
Over the past decades, stem cell-based therapy has attracted great interest as an emerging treatment in stroke in the hope that it can repair the damaged central neural networks. Stem cell therapy displays significant effects of functional improvement for ischemic stroke, offering hope for the preservation of neural tissue in the acute phase of stroke and the replacement of lost tissue in the chronic stage.
Clinical trial linked here:
Heart Disease
Macrophages and their M2 polarization driven by MSC immunomodulatory actions play a particularly important role in tendinopathy resolution.
Mesenchymal stem cells (MSCs) are extensively studied in clinical trials for treating heart diseases, particularly heart failure and ischemic heart disease. These trials focus on the safety, efficacy, and mechanisms by which MSCs may regenerate damaged cardiac tissue, improve heart function, and reduce fibrosis and inflammation.
Clinical trials linked here:
Knees
Multiple randomized controlled trials (RCTs) and meta-analyses report that intra-articular MSC injections lead to significant improvements in pain (e.g., WOMAC, VAS scores), knee function, and sometimes cartilage regeneration or preservation in OA patients. These improvements are often seen within 6 to 12 months post-injection and may last longer.
Clinical trial linked here:
Hips
Intra-articular injections of mesenchymal stem cells (MSCs) into the hip joint are an emerging treatment approach primarily studied for hip osteoarthritis (OA). Clinical trials and small studies indicate this therapy is generally safe and shows promising effectiveness in reducing pain and improving function, although definitive evidence from large randomized controlled trials (RCTs) is still lacking.
Ankles
Pain Reduction and Functional Improvement: Clinical studies report significant improvements in pain scores such as the Visual Analog Scale (VAS) and functional mobility measures like the Ankle Osteoarthritis Scale (AOS) and Foot and Ankle Ability Measure (FAAM) up to one year post-treatment with MSC therapy.
Clinical trial linked here:
Type 1 Diabetes and Focal Epilepsy
All injections contain 22.5 million live cells derived from umbilical cord blood. These are the most effective MSCs. These MSCs cells have never been frozen and are the most effective in any treatments.
Clinical trials linked here:
MScs treating Felbamate add-on therapy for drug-resistant focal epilepsy
Pain
Pain Reduction and Functional Improvement: Clinical studies report significant improvements in pain scores such as the Visual Analog Scale (VAS) and functional mobility measures like the Ankle Osteoarthritis Scale (AOS) and Foot and Ankle Ability Measure (FAAM) up to one year post-treatment with MSC therapy.
Clinical trial linked here:
Tendons
Mesenchymal stem cells (MSCs) have emerged as a promising therapeutic approach for treating tendon tears, with several clinical trials demonstrating measurable improvements in tissue healing and functional outcomes. The clinical evidence shows that MSCs can enhance tendon repair through various mechanisms, though research continues to refine optimal treatment protocols.
Mesenchymal stem cells (MSCs) have been investigated in clinical trials as a treatment for torn tendons, particularly partial tendon tears such as those in the supraspinatus (rotator cuff) or Achilles tendon. Several studies have explored the safety, efficacy, and potential regenerative effects of injecting MSCs directly into tendon lesions.
Macrophages and their M2 polarization driven by MSC immunomodulatory actions play a particularly important role in tendinopathy resolution.
Mesenchymal stem cells (MSCs) are extensively studied in clinical trials for treating heart diseases, particularly heart failure and ischemic heart disease. These trials focus on the safety, efficacy, and mechanisms by which MSCs may regenerate damaged cardiac tissue, improve heart function, and reduce fibrosis and inflammation.
Clinical trial linked here: